Evidence map›Paper›PMID 25772246›Full record

ArticleOncogene2015

Cell growth density modulates cancer cell vascular invasion via Hippo pathway activity and CXCR2 signaling.

G M Sharif, M O Schmidt, C Yi, Z Hu, B R Haddad, E Glasgow, A T Riegel, A Wellstein

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 82 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Hippo Signaling in the Endometrium.International journal of molecular sciences · 2022
    Review
  10. Article
  11. Article
  12. Tumour-associated CD204Neuropathology and applied neurobiology · 2022
    Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Cancer Cell Invasion and Metastasis in Zebrafish Models (Danio rerio).Methods in molecular biology (Clifton, N.J.) · 2021
    Article
  18. The Hippo pathway: an emerging role in urologic cancers.American journal of clinical and experimental urology · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

G M SharifLombardi Cancer Center, Georgetown University, Washington, DC, USA.
M O SchmidtLombardi Cancer Center, Georgetown University, Washington, DC, USA.
C YiLombardi Cancer Center, Georgetown University, Washington, DC, USA.
Z HuLombardi Cancer Center, Georgetown University, Washington, DC, USA.
B R HaddadLombardi Cancer Center, Georgetown University, Washington, DC, USA.
E GlasgowLombardi Cancer Center, Georgetown University, Washington, DC, USA.
A T RiegelLombardi Cancer Center, Georgetown University, Washington, DC, USA.
A WellsteinLombardi Cancer Center, Georgetown University, Washington, DC, USA.
Georgetown University · USGeorgetown University Medical Center · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
TRAINING GRANT IN TUMOR BIOLOGYT32CA009686 · NCI · GEORGETOWN UNIVERSITY · PI ANNA Tate RIEGEL, DAVID J ROBBINS · 1996 to 2026
$10.8M
SPORE IN BREAST CANCERP50CA058185 · NCI · GEORGETOWN UNIVERSITY · PI DICKSON, ROBERT B. · 1992 to 2004
$4.0M
BIOLOGY AND PATHOLOGY OF A MODULATOR OF FGFR01CA071508 · NCI · GEORGETOWN UNIVERSITY · PI WELLSTEIN, ANTON · 1997 to 2010
$2.9M
Role of AIB1 in malignant progressionR01CA113477 · NCI · GEORGETOWN UNIVERSITY · PI RIEGEL, ANNA TATE · 2005 to 2015
$2.9M
Inhibition of the ALK Receptor KinaseR01CA101811 · NCI · GEORGETOWN UNIVERSITY · PI WELLSTEIN, ANTON · 2003 to 2006
$1.6M
Conditionally reprogrammed cells as a novel tool for biobankingR33CA177466 · NCI · GEORGETOWN UNIVERSITY · PI SCHLEGEL, RICHARD, WELLSTEIN, ANTON · 2013 to 2015
$1.2M
Pancreas Cancer Specialized Program of Research Excelle*R01CA108440 · NCI · GEORGETOWN UNIVERSITY · PI WELLSTEIN, ANTON · 2003 to 2007
$1.1M
NCI NIH HHS CA113477NCI NIH HHS CA51008NCI NIH HHS CA71508NCI NIH HHS P30 CA051008NCI NIH HHS P50 CA058185NCI NIH HHS R01 CA071508NCI NIH HHS R01 CA101811NCI NIH HHS R01 CA108440NCI NIH HHS R01 CA113477NCI NIH HHS R33 CA177466NCI NIH HHS T32 CA009686
6 · The paper itself

Abstract

Metastasis of cancer cells involves multiple steps, including their dissociation from the primary tumor and invasion through the endothelial cell barrier to enter the circulation and finding their way to distant organ sites where they extravasate and establish metastatic lesions. Deficient contact inhibition is a hallmark of invasive cancer cells, yet surprisingly the vascular invasiveness of commonly studied cancer cell lines is regulated by the density at which cells are propagated in culture. Cells grown at high density were less effective at invading an endothelial monolayer than cells grown at low density. This phenotypic difference was also observed in a zebrafish model of vascular invasion of cancer cells after injection into the yolk sac and extravasation of cancer cells into tissues from the vasculature. The vascular invasive phenotypes were reversible. A kinome-wide RNA interference screen was used to identify drivers of vascular invasion by panning small hairpin RNA (shRNA) library-transduced noninvasive cancer cell populations on endothelial monolayers. The selection of invasive subpopulations showed enrichment of shRNAs targeting the large tumor suppressor 1 (LATS1) kinase that inhibits the activity of the transcriptional coactivator yes-associated protein (YAP) in the Hippo pathway. Depletion of LATS1 from noninvasive cancer cells restored the invasive phenotype. Complementary to this, inhibition or depletion of YAP inhibited invasion in vitro and in vivo. The vascular invasive phenotype was associated with a YAP-dependent upregulation of the cytokines IL6, IL8 and C-X-C motif ligand 1, 2 and 3. Antibody blockade of cytokine receptors inhibited invasion and confirmed that they are rate-limiting drivers that promote cancer cell vascular invasiveness and could provide therapeutic targets.

Indexed as

Cell MovementGene Expression Regulation, NeoplasticAdaptor Proteins, Signal TransducingAnimalsApoptosisBlotting, WesternBreast NeoplasmsCell CycleCell ProliferationCytokinesEndothelium, VascularFemaleHumansHuman Umbilical Vein Endothelial CellsMiceMice, NudeAdaptor Proteins, Signal TransducingCytokinesLATS1 protein, humanPhosphoproteinsProtein Serine-Threonine KinasesReceptors, Interleukin-8BRNA, MessengerTranscription FactorsYAP1 protein, humanYAP-Signaling Proteins

Identifiers

PMID25772246
PMCPMC4573390
OpenAlexW2022945031

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.